Equines and large animals to benefit from Creso’s new hemp plant product
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
It has been a highly productive start to the year for Creso Pharma Limited (ASX:CPH, FRA:1X8), but the company isn’t prepared to rest on its laurels and is already thinking about product launches in the second half of 2020.
One of the new products the market will see, will be a new hemp derived animal health product targeted at equines and large animals.
Creso Pharma has successfully developed anibidiol®EQUI, a flavoured micromilled hemp plant product for equines and large animals.
It was only a matter of time before Creso would announce a further product launch in its animal product vertical, having already announced this year that it commercialised anibidiol® Regular and anibidiol® Plus for small, medium-sized, and large pets to help reduce stress and aid in the functioning of the animals’ nervous systems.
As previously reported by Finfeed, Creso has now sold over three million doses of its anibidiol® product since the product was launched in late 2017, while global sales of the product grew by approximately 700% in 2019 – a major milestone.
These three million portion sachets of anibidiol® granules have benefited over 100,000 dogs in the less than two years since the product launched.
Read: Creso Pharma pursuing animal health – a fast growing segment of the cannabis market
The animal health market was worth US$70 billion in 2019 and is projected to be among the fastest growing Cannabidiol (CBD) sectors.
anibidiol®EQUI, developed in conjunction with Switzerland-based CapService is a natural plant product.
Developed over the past 12 months, the complementary feed is based on natural hemp plant components and provides the entourage effect in which the various hemp components work together to reduce stress and pain and support fast mobility recovery.
The product contains natural hemp compounds which are recognised as traditional feed components already approved for use in consumer products. This means an additional path to market for the company’s hemp-based complementary feed products without the need for regulatory approval.
anibidiol®EQUI will be mainly commercialised in LATAM, ASIAPAC and selected European countries, thus increasing the global commercial foot print.
anibidiol®EQUI is Swiss made, produced out of Swiss Good Agricultural Practice (GAP) compliant industrial hemp.
“Creso Pharma is excited to add another innovative product to our growing portfolio,” said Dr. Miri Halperin Wernli, Co-Founder and CEO of Creso Pharma said.
“anibidiol®EQUI was developed to address the equines and large animals’ needs for a natural plant based complementary feed product to support the management of stress and pain and to enhance well-being. We are pleased to have this product ready for launch later this year.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
